- Home
- ANAB vs GLOB Comparison
ANAB vs GLOB Comparison
Compare ANAB & GLOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | GLOB |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ANAB | GLOB |
|---|---|---|
| Price | $53.61 | $32.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $71.67 | $71.60 |
| AVG Volume (30 Days) | 818.3K | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $2.98 |
| Revenue Next Year | $52.14 | $5.18 |
| P/E Ratio | ★ N/A | $22.55 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $27.56 |
| 52 Week High | $73.30 | $93.56 |
Technical Indicators
Market Signals| Indicator | ANAB | GLOB |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 53.99 |
| Support Level | $52.32 | $32.50 |
| Resistance Level | $57.70 | $71.34 |
| Average True Range (ATR) | 4.55 | 1.82 |
| MACD | -0.98 | 0.41 |
| Stochastic Oscillator | 24.72 | 98.27 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.